Company Biodesix, Inc.

Equities

BDSX

US09075X1081

Healthcare Facilities & Services

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Biodesix, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
1.55 ^USD	0.00%		+18.32%	-15.76%

May. 08	Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Number of employees: 217

USD in Million	2022	Weight	2023	Weight	Delta
Lung Diagnostic 91.9 %	29	76.7 %	45	91.9 %	+54.05%
Biopharma Services and Other 7.9 %	4	9.6 %	4	7.9 %	+6.02%
COVID-19 0.1 %	5	13.7 %	0	0.1 %	-98.91%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	38	100.0 %	49	100.0 %	+28.46%

Managers	Title	Age	Since
Scott Hutton CEO	Chief Executive Officer	52	-
Robin Cowie DFI	Director of Finance/CFO	44	11-02-28
James R. Jett CTO	Chief Tech/Sci/R&D Officer	-	15-12-31
Steven C. Springmeyer CTO	Chief Tech/Sci/R&D Officer	-	14-12-31
Christopher Vazquez AUD	Comptroller/Controller/Auditor	50	21-02-01
Kieran O’Kane PRN	Corporate Officer/Principal	47	18-01-31
Gary Pestano PRN	Corporate Officer/Principal	57	12-02-29

Members of the board	Title	Age	Since
John Patience CHM	Chairman	76	08-05-31
Jack Schuler BRD	Director/Board Member	83	11-12-31
Jon Kayyem BRD	Director/Board Member	60	21-12-05
Hany Massarany BRD	Director/Board Member	62	20-07-19
Matthew Strobeck BRD	Director/Board Member	51	11-12-31
Scott Hutton CEO	Chief Executive Officer	52	-
Jean Franchi BRD	Director/Board Member	57	20-03-31
Charles Watts BRD	Director/Board Member	81	19-06-30
Lawrence Kennedy BRD	Director/Board Member	52	23-01-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	113,627,715	42,579,124 ( 37.47 %)	0	37.47 %

Name	Equities	%	Valuation
Jack Schuler 31.68 %	30,707,722	31.68 %	44 M $
Lawrence Kennedy 21.66 %	21,000,243	21.66 %	30 M $
John Patience 7.560 %	7,328,336	7.560 %	10 M $
Birchview Capital LP 5.357 %	5,193,336	5.357 %	7 M $
AIGH Capital Management LLC 4.806 %	4,658,946	4.806 %	7 M $
Robert Cawthorn 3.767 %	3,652,220	3.767 %	5 M $
AIGH Capital Management LLC 3.516 %	3,408,946	3.516 %	5 M $
Matthew Strobeck 3.114 %	3,018,940	3.114 %	4 M $
Birchview Capital LP 2.382 %	2,308,712	2.382 %	3 M $
Worth Venture Partners LLC 1.178 %	1,141,794	1.178 %	2 M $

Biodesix, Inc.

2970 Wilderness Place Suite 100

80301, Boulder

http://www.biodesix.com

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.55 USD

Average target price

3.25 USD

Spread / Average Target

+109.68%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
BIODESIX, INC.	-15.76%	176M
SONIC HEALTHCARE LIMITED	-17.08%	8.39B
RADNET, INC.	+54.07%	3.74B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-37.54%	2.55B
SYNLAB AG	-9.63%	2.48B
DR. LAL PATHLABS LIMITED	-13.43%	2.32B
NEOGENOMICS, INC.	-4.20%	1.93B
FLEURY S.A.	-18.24%	1.6B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-36.41%	1.28B
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.08B

Medical & Diagnostic Laboratories